Integrin alpha 5/CD49e Antibody (238307) [HRP]
Novus Biologicals, part of Bio-Techne | Catalog # FAB1864H
Conjugate
Catalog #
Key Product Details
Species Reactivity
Human
Applications
Adhesion Activation, CyTOF-ready, Flow Cytometry, Immunocytochemistry
Label
HRP
Antibody Source
Monoclonal Mouse IgG1 Clone # 238307
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
Mouse myeloma cell line NS0-derived recombinant human Integrin alpha5/CD49e
Phe42-Tyr995
Accession # P08648
Phe42-Tyr995
Accession # P08648
Specificity
Detects human Integrin alpha5/CD49e.
Clonality
Monoclonal
Host
Mouse
Isotype
IgG1
Applications for Integrin alpha 5/CD49e Antibody (238307) [HRP]
Application
Recommended Usage
Adhesion Activation
Optimal dilutions of this antibody should be experimentally determined.
CyTOF-ready
Optimal dilutions of this antibody should be experimentally determined.
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Immunocytochemistry
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
0
Formulation
PBS
Preservative
No Preservative
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: Integrin alpha 5/CD49e
Alternate Names
CD49e, ITGA5, VLA-5 alpha
Gene Symbol
ITGA5
Additional Integrin alpha 5/CD49e Products
Product Documents for Integrin alpha 5/CD49e Antibody (238307) [HRP]
Product Specific Notices for Integrin alpha 5/CD49e Antibody (238307) [HRP]
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...